Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Docetaxel, and Capecitabine in Metastatic Breast Cancer
NCT00845910Phase 2Terminated
- Sponsor
- Roche
- Start
- May 2009
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in breast cancer, sponsored by Roche. Started May 2009; status: terminated.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00845910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00845910.